Povidon JOD (Solution) Instructions for Use
Marketing Authorization Holder
Zorka Pharma (Serbia)
ATC Code
G01AX11 (Povidone-iodine)
Active Substance
Povidone-iodine (BAN)
Dosage Forms
| Povidon JOD | Concentrated solution for topical use 8.5%: 50 ml bottle | |
| Vaginal suppositories 200 mg: 14 pcs. | ||
| Ointment for external use 10% (10 g/100 g): 40 g tube | ||
| Foaming solution for external use 7.5% (7.5 g/100 ml): 500 ml or 5 L bottle | ||
| Solution for external use 10% (10 g/100 ml): 100 ml, 500 ml or 5 L bottle |
Dosage Form, Packaging, and Composition
Solution for external use 10% is a dark brown liquid with a characteristic odor of iodine.
| 100 ml | |
| Povidone-iodine | 10 g |
Excipients: nonoxynol, glycerol, disodium hydrogen phosphate 12-hydrate, citric acid, sodium hydroxide, demineralized water.
100 ml – plastic bottles.
500 ml – plastic bottles.
5 L – plastic canisters.
Foaming solution for external use 7.5% is a dark brown liquid with a characteristic odor of iodine; foams when shaken.
| 100 ml | |
| Povidone-iodine | 7.5 g |
Excipients: diethanolamide of lauric acid, ammonium nonylphenol ethoxylate sulfonic acid, sodium phosphate 12-hydrate, citric acid, demineralized water.
500 ml – plastic bottles.
5 L – plastic canisters.
| Concentrated solution for topical use 8.5% | 1 ml |
| Povidone-iodine | 85 mg |
50 ml – plastic bottles.
Ointment for external use 10% is dark brown, homogeneous, with a characteristic odor of iodine.
| 100 g | |
| Povidone-iodine | 10 g |
Excipients: macrogol 4000, purified water.
40 g – aluminum tubes (1) – cardboard packs.
| Vaginal suppositories | 1 supp. |
| Povidone-iodine | 200 mg |
7 pcs. – contour cell packs (2) – cardboard packs.
Clinical-Pharmacological Group
Topical antiseptic for use in gynecology
Pharmacotherapeutic Group
Antiseptic
Pharmacological Action
An antiseptic and disinfectant drug. When released from the complex with polyvinylpyrrolidone upon contact with the skin and mucous membranes, iodine forms iodamines with bacterial cell proteins, coagulates them and causes the death of microorganisms. It has a rapid bactericidal effect on gram-positive and gram-negative bacteria (except for Mycobacterium tuberculosis).
Also active against fungi, viruses, protozoa.
It has a longer duration of action compared to a solution of inorganic iodine.
Pharmacokinetics
When applied externally, the reabsorption of iodine from the surface of the skin or mucous membrane or wounds is extremely insignificant.
Indications
Solution for external use 10%
- Treatment and prevention of wound infections in surgery, traumatology, combustiology, dentistry;
- Treatment of bacterial, fungal and viral skin infections, prevention of superinfection in dermatological practice;
- Treatment of bedsores, trophic ulcers, diabetic foot;
- Disinfection of the skin and mucous membranes of patients in preparation for surgical interventions, invasive studies (including punctures, biopsies, injections);
- Disinfection of the skin around drains, catheters, probes;
- Disinfection of the oral cavity during dental operations;
- Disinfection of the birth canal, during minor gynecological operations (including artificial termination of pregnancy, insertion of an intrauterine device, coagulation of erosion and polyp).
Foaming solution for external use 7.5%
- Disinfecting baths – for complete and partial treatment of the patient before operations;
- Hygienic treatment of patients;
- Hygienic hand treatment when in contact with infected patients;
- Treatment of instruments (non-metallic) and patient care items.
Concentrated solution for topical use 8.5%
- For mouth and throat rinsing.
Ointment for external use 10%
- Bacterial and fungal skin infections;
- Burns;
- Trophic ulcers;
- Bedsores;
- Infectious dermatitis;
- Abrasions;
- Wounds.
Vaginal suppositories
- Candidiasis;
- Trichomoniasis;
- Non-specific vaginitis.
ICD codes
| ICD-10 code | Indication |
| A59 | Trichomoniasis |
| B09 | Unspecified viral infection characterized by skin and mucous membrane lesions |
| B35.2 | Mycosis of hands |
| B35.3 | Tinea pedis |
| B35.4 | Tinea corporis |
| B35.6 | Tinea cruris |
| B37.2 | Candidiasis of skin and nails |
| B37.3 | Candidiasis of vulva and vagina |
| E10.5 | Insulin-dependent diabetes mellitus with peripheral circulatory complications (including ulcer, gangrene) |
| E11.5 | Non-insulin-dependent diabetes mellitus with peripheral circulatory complications (including ulcer, gangrene) |
| I83.2 | Varicose veins of lower extremities with ulcer and inflammation |
| L01 | Impetigo |
| L08.0 | Pyoderma |
| L08.8 | Other specified local infections of skin and subcutaneous tissue |
| L30.3 | Infectious dermatitis (infectious eczema) |
| L89 | Decubitus ulcer and pressure area |
| L98.4 | Chronic skin ulcer, not elsewhere classified |
| N76 | Other inflammatory diseases of vagina and vulva |
| N77.1 | Vaginitis, vulvitis and vulvovaginitis in infectious and parasitic diseases classified elsewhere |
| T14.0 | Superficial injury of unspecified body region (including abrasion, bruise, contusion, hematoma, bite of nonvenomous insect) |
| T30 | Burns and corrosions of unspecified body region |
| T79.3 | Posttraumatic wound infection, not elsewhere classified |
| Z29.8 | Other specified prophylactic measures |
| Z51.4 | Preparatory procedures for subsequent treatment or examination, not elsewhere classified |
| ICD-11 code | Indication |
| 1A92 | Trichomoniasis |
| 1B72.0 | Bullous impetigo |
| 1B72.1 | Nonbullous impetigo |
| 1B72.Z | Impetigo, unspecified |
| 1B7Y | Other specified pyogenic bacterial infections of skin or subcutaneous tissue |
| 1C44 | Non-pyogenic bacterial infections of skin |
| 1F0Z | Viral infections characterized by skin or mucous membrane lesions, unspecified |
| 1F23.10 | Candidiasis of vulva and vagina |
| 1F23.1Z | Candidiasis of skin or mucous membranes, unspecified |
| 1F28.2 | Dermatophytosis of foot |
| 1F28.3 | Genitofemoral dermatophytosis |
| 1F28.Y | Other specified dermatophytosis |
| 1F65 | Enterobiasis |
| 1H0Z | Unspecified infection |
| 5A10 | Type 1 diabetes mellitus |
| 5A11 | Type 2 diabetes mellitus |
| BD74.Z | Chronic venous insufficiency of lower extremities, unspecified |
| EA40 | Tropical phagedenic ulcer |
| EA50.3 | Staphylococcal scarlet fever |
| EA88.0Z | Infectious dermatitis, unspecified |
| EB21 | Pyoderma gangrenosum |
| EF60 | Ischemic ulceration of the skin |
| EH90.Z | Pressure ulcer of unspecified degree |
| EH92 | Dermatoses provoked by friction or mechanical impact |
| EH92.1 | Blister due to friction |
| EM0Z | Unspecified skin disorder |
| GA00 | Vulvitis |
| GA02.Z | Unspecified vaginitis |
| GA0Z | Inflammatory diseases of female genital tract, unspecified |
| ME60.2 | Ulcerative skin lesion of unspecified nature |
| ND56.0 | Superficial injury of unspecified body region |
| NE11 | Burn of unspecified body region |
| NF0A.3 | Posttraumatic wound infection, not elsewhere classified |
| QB9A | Preparatory procedures for subsequent treatment |
| QC05.Z | Prophylactic measures, unspecified |
| 1A94.0 | Genital or urogenital tract infection caused by Herpes simplex virus |
| GA41 | Ulcerative or erosive diseases of vulva |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Solution for external use 10%
For treatment of the skin and mucous membranes, it is used undiluted for lubrication, irrigation or as a wet compress.
For use in drainage systems, the solution is diluted from 10 to 100 times.
Foaming solution for external use 7.5%
For disinfection of the hands of surgical personnel, 5 ml of undiluted solution is applied to pre-washed hands and evenly distributed up to the elbows, rubbing for 2.5 minutes with palms or a brush until foam forms (the foam is washed off with sterile water or removed with a sterile napkin); then the treatment is repeated.
For disinfection of the skin of the operating field, the drug is applied to the shaved and moistened with water skin and rubbed in to form foam. 1 ml of the drug is sufficient for application to a skin surface of 50-70 cm2 by rubbing for 5 minutes. The foam is removed with a sterile gauze pad soaked in water, after which the skin is lubricated with undiluted solution and dried.
Concentrated solution for topical use 8.5%
For mouth and throat rinsing, 1 teaspoon of the solution is diluted in 1/4 glass of water. Rinsing is carried out several times a day.
Ointment for external use 10%
The ointment is applied in a thin layer to the affected area 2-3 times a day, it can be used under an occlusive dressing.
Vaginal suppositories
Prescribed 1-2 pcs./day. The duration of treatment is 14 days or as directed by a doctor. Before using vaginal suppositories, sanitary treatment is necessary.
Adverse Reactions
Possible allergic reactions.
Local reactions in some cases allergic reactions to iodine – hyperemia, burning, itching, swelling, pain (drug withdrawal is required).
Systemic reactions when applied to a large area of the wound surface and mucous membranes, systemic reabsorption of iodine is possible, which can cause neutropenia, as well as change the results of thyroid function tests; with long-term use (more than 7-10 days) phenomena of iodism are possible (including metallic taste in the mouth, increased salivation, swelling of the eyelids or larynx).
Contraindications
- Hyperthyroidism;
- Thyroid adenoma;
- Heart failure;
- Chronic renal failure;
- Dermatitis herpetiformis Duhring;
- Simultaneous use of radioactive iodine;
- Premature and newborn infants;
- Children under 8 years of age (ointment for external use);
- Pregnancy;
- Lactation;
- Hypersensitivity to iodine and other components of the drug.
Use in Pregnancy and Lactation
The drug is contraindicated for use during pregnancy and during lactation (breastfeeding).
Use in Renal Impairment
Contraindicated in chronic renal failure.
Pediatric Use
The drug is contraindicated in children under 8 years of age.
Special Precautions
If side effects develop, drug withdrawal is required.
The presence of blood and pus may reduce the antimicrobial effect of the drug.
Do not use for insect bites, domestic and wild animal bites.
The patient should be warned about the need to consult a doctor if systemic reactions occur.
It is necessary to ensure that no excess solution remains under the patient.
A colored film is formed at the application site, which persists until the entire amount of active iodine is released, i.e., its disappearance means the cessation of the drug’s action. The color on the skin and tissues is easily washed off with water.
Do not heat before use.
Overdose
Symptoms local irritation, allergic reactions.
Treatment reducing the frequency of application or complete discontinuation of the drug.
Drug Interactions
Povidone iodine is incompatible with other disinfectants and antiseptics, especially those containing alkalis, enzymes and mercury.
In an acidic environment, the activity of the drug decreases.
Storage Conditions
List B. Solutions should be stored in a place protected from light, tightly closed, at a temperature from 0°C (32°F) to 25°C (77°F).
The ointment should be stored in the original packaging at a temperature from 0°C (32°F) to 25°C (77°F).
Shelf Life
The shelf life of the drug in the form of a solution for external use 10%, ointment for external use 10% and vaginal suppositories is 3 years.
The shelf life of the foaming solution for external use 7.5% and the concentrated solution for topical use 8.5% is 2 years.
Dispensing Status
The drug is approved for use as an over-the-counter product.
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer